Monoclonal Or Polyclonal Antibody Or Immunoglobulin Or Fragment Thereof That Is Conjugated Or Adsorbed (e.g., Adsorbed To A Solid Support, Etc.) Patents (Class 530/391.1)
-
Patent number: 11965882Abstract: Provided are affinity-based methods of isolating biological entities via a surface antigen from a sample with non-chromatographic and chromatographic methods being provided. Also provided is a dextran polymer, kits for use in the method of isolating a biological entity and an apparatus for performing the methods.Type: GrantFiled: February 1, 2021Date of Patent: April 23, 2024Assignee: CELL.COPEDIA GMBHInventor: Herbert Stadler
-
Patent number: 11946055Abstract: Disclosed herein are methods, compositions, and kits for engineering proteins using error-prone orthogonal replication (epOrthoRep) and yeast surface display (YSD).Type: GrantFiled: December 9, 2021Date of Patent: April 2, 2024Assignees: The Regents of the University of California, President and Fellows of Harvard CollegeInventors: Chang C. Liu, Alon Wellner, Ziwei Zhong, Arjun Ravikumar, Andrew Kruse, Conor Thomas McMahon
-
Patent number: 11938194Abstract: The invention provides modified heavy chain constant regions including a cysteine at position 295 by EU numbering and optionally at position 239 by EU numbering. These cysteine residues provide sites for conjugation to a drug or label. When both cysteines are present in a normal heterodimeric antibody format, there are four such sites per molecule of antibody allowing a stoichiometry of one molecule of antibody to four of drug or label. Selection of the cysteine at position 295 with or without cysteine at position 239 is advantageous over cysteines at many other positions due to ease of expression, stability and cytotoxicity.Type: GrantFiled: February 28, 2018Date of Patent: March 26, 2024Assignee: SEAGEN INC.Inventors: Andrew Waight, Chris Leiske, Travis Biechele, Django Sussman, Patrick Burke, Jocelyn Leiske
-
Patent number: 11912754Abstract: The present application provides an antibody fusion protein comprising a vascular endothelial growth factor receptor (VEGFR) fused to the C-terminus of the antibody light chain. Also provided are methods of making and using these antibody fusion proteins.Type: GrantFiled: October 11, 2018Date of Patent: February 27, 2024Assignee: IMMUNOWAKE INC.Inventor: Xiaoyun Wu
-
Patent number: 11912755Abstract: Materials and methods for using polypeptides containing fragments and variants of endostatin to treat fibrosis are described herein.Type: GrantFiled: November 9, 2020Date of Patent: February 27, 2024Assignees: Bio, Inc., Novici Biotech LLC, MUSC Foundation for Research DevelopmentInventors: Carol Feghali-Bostwick, Terence E. Ryan, Hal S. Padgett, Matthew McGee
-
Patent number: 11912751Abstract: This invention discloses a bifunctional TGF-B/immune checkpoint fusion gene and protein with anti-inflammatory activity that represents a new class of therapy for Immune disorders, immune dysregulation, and autoimmune diseases. The bifunctional TGF-B/immune checkpoint fusion gene and protein include: (i) a TGF-B domain consists of TGF-B1 (ii) an immune checkpoint consisting of PD-L1, (iii) a flexible peptide linker that links two TGF-B domains resulting in a dimeric TGF-B construct wherein the dimeric form of the TGF-B ligand is important for its binding and functional activity, and (iv) a rigid peptide linker, wherein the dimeric TGF-B ligand is linked to the immune checkpoint ligand. A unique feature of this invention is the engineering of a dimeric TGF-B1 domain in the TGF-B1/PD-L1 fusion protein which was experimentally shown to be important in its binding to its TFGBR1 receptor and its functional activity.Type: GrantFiled: January 19, 2021Date of Patent: February 27, 2024Assignee: Globetek Science FoundationInventor: Samuel Dequina Bernal
-
Patent number: 11903999Abstract: A method of inducing cell death in a glioblastoma multiforme cancer cell is provided, the method comprising administering to the cell a combination of therapeutic agents comprising: saposin C and dioleoylphosphatidylserine (SapC-DOPS), and nucleolin aptamer AS1411, wherein cell death of the cancer cell is induced. Also provided are methods of treating glioblastoma multiforme, methods of inhibiting growth of a glioblastoma multiforme tumor, kits, and pharmaceutical compositions comprising SapC-DOPS and AS1411.Type: GrantFiled: October 15, 2018Date of Patent: February 20, 2024Assignee: University of CincinnatiInventors: Xiaoyang Qi, Nikhil Shukla
-
Patent number: 11879158Abstract: The present disclosure provides a system and method for the detection of rare mutations and copy number variations in cell free polynucleotides. Generally, the systems and methods comprise sample preparation, or the extraction and isolation of cell free polynucleotide sequences from a bodily fluid; subsequent sequencing of cell free polynucleotides by techniques known in the art; and application of bioinformatics tools to detect rare mutations and copy number variations as compared to a reference. The systems and methods also may contain a database or collection of different rare mutations or copy number variation profiles of different diseases, to be used as additional references in aiding detection of rare mutations, copy number variation profiling or general genetic profiling of a disease.Type: GrantFiled: March 16, 2022Date of Patent: January 23, 2024Assignee: Guardant Health, Inc.Inventor: AmirAli Talasaz
-
Patent number: 11846622Abstract: Provided are aptamer-functionalized graphene sensors, capable of detecting various analytes, including toxins, at comparatively low concentrations. Also provided are methods of fabricating and using such aptamer-functionalized graphene sensors.Type: GrantFiled: March 12, 2019Date of Patent: December 19, 2023Assignee: The Trustees of the University of PennsylvaniaInventors: Alan T. Johnson, Jr., Jinglei Ping, Steven Vitale, Chengyu Wen
-
Patent number: 11834498Abstract: The present disclosure provides biparatopic antibodies comprising polypeptides that bind to folate receptor alpha (FR?) compositions comprising such biparatopic antibodies. In a specific aspect, the biparatopic antibodies bind to FR? and modulate FR? activity. The present disclosure also provides methods for treating disorders, such as cancer, by administering a biparatopic antibody that specifically binds to FR? and modulates FR? activity.Type: GrantFiled: June 10, 2022Date of Patent: December 5, 2023Assignee: ImmunoGen, Inc.Inventors: Olga Ab, Neeraj Kohli, Thomas Chittenden, Julianto Setiady
-
Patent number: 11827703Abstract: The present disclosure relates to antibody-drug conjugates (ADCs) wherein one or more active agents are conjugated to an anti-CD19 antibody through a linker. The linker may comprise a unit that covalently links active agents to the antibody. The disclosure further relates to monoclonal antibodies and antigen binding fragments, variants, multimeric versions, or bispecifics thereof that specifically bind CD19, as well as methods of making and using these anti-CD19 antibodies and antigen-binding fragments thereof in a variety of therapeutic, diagnostic and prophylactic indications.Type: GrantFiled: May 9, 2019Date of Patent: November 28, 2023Assignees: LegoChem Biosciences, Inc., NovImmune, SAInventors: Ho Young Song, Yun Hee Park, Sung Min Kim, Hyoung Rae Kim, Ji Hye Oh, Hyun Min Ryu, Jeiwook Chae, Yeong Soo Oh, Yong Zu Kim, Maureen Deehan, Nicolas Fischer
-
Patent number: 11827691Abstract: This invention relates to molecules, particularly polypeptides, more particularly fusion proteins that include a serpin polypeptide or an amino acid sequence that is derived from a serpin and second polypeptide comprising of at least one the following: an Fc polypeptide or an amino acid sequence that is derived from an Fc polypeptide; a cytokine targeting polypeptide or a sequence derived from a cytokine targeting polypeptide; a (whey acidic protein) WAP domain containing polypeptide or a sequence derived from a WAP containing polypeptide; and an albumin polypeptide or an amino acid sequence that is derived from a serum albumin polypeptide. This invention also relates to methods of using such molecules in a variety of therapeutic and diagnostic indications, as well as methods of producing such molecules.Type: GrantFiled: June 22, 2020Date of Patent: November 28, 2023Assignee: InhibRx, Inc.Inventors: Brendan P. Eckelman, John C. Timmer, Peter L. Nguy, Grant B. Guenther, Quinn Deveraux
-
Patent number: 11808722Abstract: Sensors having an advantageous design and methods for fabricating such sensors are generally provided. Some sensors described herein comprise pairs of electrodes having radial symmetry, pairs of nested electrodes, and/or nanowires. Some embodiments relate to fabricating electrodes by methods in which nanowires are deposited from a fluid contacted with a substrate in a manner such that it evaporates and is replenished.Type: GrantFiled: August 29, 2022Date of Patent: November 7, 2023Assignee: NanoDX, Inc.Inventors: Farhad Khosravi, David Bastable, Sergey A. Dryga
-
Patent number: 11795203Abstract: Disclosed are a protein heterodimer and the use thereof. The protein heterodimer comprises a first polypeptide chain and a second polypeptide chain different from the first polypeptide chain, wherein the first polypeptide chain comprises IL(interleukin)12a and a first factor fused to IL12a, the second polypeptide chain comprises IL12b and a second factor fused to IL12b, and the first factor and the second factor are each independently selected from a group consisting of: IL2, GMCSF(granulocyte-macrophage colony-stimulating factor), IL7, IL15, IL21 and FLT3L(FMS-like tyrosine kinase 3 ligand). The protein heterodimer can be used for treating tumors.Type: GrantFiled: July 30, 2019Date of Patent: October 24, 2023Inventor: Jinyu Zhang
-
Patent number: 11795456Abstract: Compositions and methods for treating or inactivating viruses in a subject in need thereof are provided herein. Exemplary compositions include nucleic acids encoding an RNA-guided endonuclease and a guide RNA that is complementary to a target sequence in a virus. The RNA-guided endonuclease specifically targets viral nucleic acid sequences for destruction and suppression of that virus in a host cell in vitro or in vivo.Type: GrantFiled: April 15, 2019Date of Patent: October 24, 2023Assignee: Georgia Tech Research CorporationInventors: Swapnil Bawage, Pooja M. Tiwari, Philip J. Santangelo
-
Patent number: 11786603Abstract: Provided herein are methods and compositions for site-specific conjugation of antibodies in the presence of a transglutaminase.Type: GrantFiled: February 24, 2017Date of Patent: October 17, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Amy Han, William Olson, Christopher D'Souza
-
Patent number: 11732038Abstract: The invention relates to novel cell-binding agent-cytotoxic agent conjugates, wherein the cell-binding agent (CBA) is covalently linked to the cytotoxic agent through an aldehyde group obtained from oxidation of a 2-hydroxyethylamine moiety on the CBA. The invention also provides methods of preparing the conjugates of the present invention. The invention further provides composition and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the conjugates of the invention.Type: GrantFiled: February 12, 2021Date of Patent: August 22, 2023Assignee: IMMUNOGEN, INC.Inventors: Nathan Elliott Fishkin, Daniel J. Tavares, Lingyun Rui, Luke B. Harris, Manami Shizuka, Michael Louis Miller, Ravi V. J. Chari
-
Patent number: 11733246Abstract: The present application provides stable heterobiligands made up of peptide-based FOLR1 ligands and folate (the ligand of FOLR1) and methods of use of the heterobiligands as detection, imaging, diagnostic, and therapeutic agents. The application further provides methods of manufacturing FOLR1 heterobiligands, capture agents, and imaging agents.Type: GrantFiled: January 12, 2022Date of Patent: August 22, 2023Assignee: INDI MOLECULAR, INC.Inventors: Heather Dawn Agnew, Anders Eliasen, Bert Tsunyin Lai
-
Patent number: 11674883Abstract: The present invention is related to correct the errors in instruments, operation, and others using intelligent monitoring structures and machine learning, and others.Type: GrantFiled: December 29, 2021Date of Patent: June 13, 2023Assignee: Essenlix CorporationInventors: Stephen Y. Chou, Wei Ding, Wu Chou, Jun Tian, Yuecheng Zhang, Mingquan Wu, Xing Li
-
Patent number: 11661631Abstract: Disclosed herein include systems, methods, compositions, and kits for determining protein expression and gene expression simultaneously and for sample indexing. In some embodiments, an oligonucleotide associated with a cellular component-binding reagent (e.g., an antibody) comprises one or more of a unique molecular label sequence, a primer adapter, antibody-specific barcode sequence, an alignment sequence, and/or a poly(A) sequence. In some embodiments, the oligonucleotide is associated with the cellular component-binding reagent via a linker (e.g., 5AmMC12).Type: GrantFiled: January 21, 2020Date of Patent: May 30, 2023Assignee: Becton, Dickinson and CompanyInventors: Eleen Shum, Katherine Lazaruk, Dennis E. Prosen, Devon Jensen, David Rosenfeld, Janice H. Lai, James Ghadiali, Christina Chang
-
Patent number: 11662349Abstract: The present invention relates to sensors and methods for detecting carbohydrates, such as lactose, in a sample. The sensors and methods may also be used to determine the amount of carbohydrate in the sample.Type: GrantFiled: August 7, 2018Date of Patent: May 30, 2023Assignee: Commonwealth Scientific and Industrial Research OrganisationInventors: Karine Caron, Stephen Charles Trowell
-
Patent number: 11560423Abstract: The present invention relates to isolated monoclonal antibodies (mAbs) and/or antigen-binding fragments thereof that specifically recognize indoxyl sulfate, a protein-bound uremic toxin, and uses of such isolated anti-IS mAbs and/or antigen-binding fragments thereof to create immunoassay methods applied in theragnosis of IS-related diseases.Type: GrantFiled: June 15, 2020Date of Patent: January 24, 2023Assignee: LEADGENE BIOMEDICAL, INC.Inventors: Yung-Chun Chuang, Yu-Wei Cheng, Chih-Hui Kao
-
Patent number: 11542339Abstract: Provided is an antibody for treating a cancer, more specifically, an anti-CD43 antibody binding to an extracellular domain of CD43, compositions for treating a cancer or inhibiting a cancer stem cell comprising the antibody as an active ingredient, and methods for screening an agent of inhibiting a cancer stem cell.Type: GrantFiled: May 11, 2020Date of Patent: January 3, 2023Assignee: APROGEN INC.Inventors: Kwon Pyo Hong, Sangsoon Yoon, Irene Koukoulas, Vincent Batori, Briony Cristiano, David S Wilson, Jr., George Kopsidas
-
Patent number: 11542301Abstract: The present application addresses the problem of providing an Fc-binding protein having an improved antibody separation ability. The present application also addresses the problem of providing a high-accuracy antibody separation method using an insoluble carrier having the protein immobilized thereon. The problems can be solved by: an Fc-binding protein in which at least an amino acid substitution at a specific position therein occurs and which has reduced affinity for an antibody; and an antibody separation method including allowing an equilibration buffer solution to pass through a column in which an insoluble carrier having the protein immobilized thereon is filled to equilibrate the column, adding a solution containing an antibody to cause the adsorption of the antibody onto the carrier, and eluting the antibody adsorbed on the carrier using an elution solution.Type: GrantFiled: February 7, 2018Date of Patent: January 3, 2023Assignee: TOSOH CORPORATIONInventors: Yosuke Terao, Yoshiharu Asaoka, Ryoko Otake, Satoshi Endo, Naoki Yamanaka, Yukie Yamamoto, Seigo Oe
-
Patent number: 11434295Abstract: The present invention relates to immunoglobulins that bind Fc?RIIb+ cells and coengage the antigen on the cell's surface and an Fc?RIIb on the cell's surface, methods for their generation, and methods for using the immunoglobulins.Type: GrantFiled: November 10, 2011Date of Patent: September 6, 2022Assignee: XENCOR, INC.Inventors: Seung Yup Chu, John R. Desjarlais, Sher Bahadur Karki, Gregory Alan Lazar, Gregory L. Moore, Igor Vostiar
-
Patent number: 11406719Abstract: The present invention provides dichromic fluorescent compounds, as well as processes for making and methods for using the dichromic fluorescent compounds.Type: GrantFiled: April 4, 2016Date of Patent: August 9, 2022Assignee: Washington UniversityInventors: Samuel Achilefu, Zongren Zhang, Mikhail Berezin
-
Patent number: 11353450Abstract: Methods and Raman detection agents for detecting an analyte in a sample are provided. Methods described herein may comprise steps of providing a 3D diagnostic substrate presenting a capture agent for the analyte or an analyte complex; exposing the sample to the substrate and to a Raman detection agent, allowing analyte in the sample to bind to the capture agent of the diagnostic substrate and an affinity component of the Raman detection agent; and detecting the Raman detection agent bound to the 3D diagnostic substrate by Raman spectroscopy, thereby detecting the presence of the analyte in the sample. Raman detection agents described herein may comprise a Raman signal-enhancing metal nanoparticle carrying both a Raman reporter and an affinity component for binding to the analyte or the complex formed between the analyte and the capture agent on the 3D diagnostic substrate.Type: GrantFiled: November 25, 2017Date of Patent: June 7, 2022Assignee: MedMira Inc.Inventors: Neeraj Vats, Hok Ping Hui
-
Patent number: 11279771Abstract: The application discloses bispecific TFPI antibodies that are capable of specifically and simultaneously binding two epitopes within TFPI (1-161). Such bispecific antibodies strongly enhance thrombin generation by neutralising TFPI, even where the concentration of TFPI is elevated. Bispecific antibodies of the invention or compositions comprising them may be used for the treatment of subjects with a coagulopathy.Type: GrantFiled: September 17, 2015Date of Patent: March 22, 2022Assignee: NOVO NORDISK A/SInventors: Helle Heibroch Petersen, Berit Olsen Krogh, Jens Breinholt, Mikael Kofod-Hansen, Ida Hilden
-
Patent number: 11220556Abstract: The present invention provides compounds producing compounds having the structure (I). Wherein A is a first polypeptide component of the compound; wherein C is a second polypeptide component of the compound, which polypeptide component comprises consecutive amino acids which (i) are identical to a stretch of consecutive amino acids present in a chain of an Fc domain of an antibody; (ii) bind to an Fc receptor; and (iii) have at their N-terminus a sequence selected from the group consisting of a cysteine, selenocysteine, CP, CPXCP (where X=P, R, or S) (SEQ ID NOs: 128-130), CDKTHTCPPCP (SEQ ID NO: 131), CVECPPCP (SEQ ID NO 132), CCVECPPCP (SEQ ID NO 133) and CDTPPPCPRCP (SEQ ID NO 134), wherein B is a chemical structure linking A and C; wherein the dashed line between B and C represents a peptidyl linkage; wherein the solid line between A and B represents a nonpeptidyl linkage comprising the structure (II).Type: GrantFiled: March 14, 2014Date of Patent: January 11, 2022Assignee: BIOMOLECULAR HOLDINGS LLCInventor: Daniel Capon
-
Patent number: 11098120Abstract: Methods of modulating the immune systems of patients suffering from cancers that do not bear, or do not uniformly bear, surface CD3 are provided. The methods involve administering an anti-CD3 immunotoxin (e.g. A-dmDT390-bisFv(UCHT1)), to the patient so as to cause the patient's immune system to recognize and destroy non-CD3 cancer cells.Type: GrantFiled: October 5, 2018Date of Patent: August 24, 2021Assignee: ANGIMMUNE, LLCInventor: David M. Neville
-
Patent number: 11066459Abstract: The present invention provides a compound having the structure: A-B - - - Z wherein A is a biologically active structure of the compound; wherein Z is a protein component of the compound, which protein component comprises one or more polypeptides, wherein at least one of the one or more polypeptides comprises consecutive amino acids which (i) are identical to a stretch of consecutive amino acids present in a chain of an Fc domain of an antibody; (ii) bind to an Fc receptor; and (iii) have at their N-terminus a sequence selected from the group consisting of a cysteine or selenocysteine; wherein the dashed line between B and Z represents a peptidyl linkage; and wherein the solid line between A and B represents a nonpeptidyl linkage, as well as intermediates dimers thereof, and processes of producing the compounds of the invention.Type: GrantFiled: March 13, 2015Date of Patent: July 20, 2021Assignee: BIOMOLECULAR HOLDINGS LLCInventor: Daniel J. Capon
-
Patent number: 10660966Abstract: A method for removing or controlling or quantifying the presence of aldehydes, in particular acetaldehyde, is described. Such a method is useful in prolonging the shelf life of a pharmaceutical product.Type: GrantFiled: December 4, 2015Date of Patent: May 26, 2020Assignee: GE HEALTHCARE LIMITEDInventors: Torgrim Engell, Julian Grigg, Dimitrios Mantzilas, Dag M. Evje
-
Patent number: 10655168Abstract: Compositions comprising covalently modified and mutated biotin-binding proteins, particularly biotin-binding proteins having a negative charge at physiological pH, are provided. Methods of producing such proteins are also provided, as are methods of immobilizing, sequencing, and making nucleic acids employing such proteins.Type: GrantFiled: December 21, 2018Date of Patent: May 19, 2020Assignee: Pacific Biosciences of California, Inc.Inventors: Satwik Kamtekar, Lubomir Sebo, Leewin Chern, Thomas Linsky, Jeremiah Hanes, Erik Miller, Ying Yang, Stephen Yue
-
Patent number: 10370399Abstract: The invention relates generally to a calicheamicin molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody directly conjugated by a disulfide to one or more calicheamicin molecules.Type: GrantFiled: October 19, 2016Date of Patent: August 6, 2019Assignee: Genentech, Inc.Inventor: Thomas Pillow
-
Patent number: 10314922Abstract: A type of trimaleimide linkers and uses thereof are disclosed. The trimaleimide linkers can be applied for preparation of antibody-drug conjugate as shown by formula I: L-(T-A-D)n I wherein, L is an antibody, antibody fragment or protein; T is a trimaleimide linker; A is a cleavable linker group or a noncleavable linker; D is a drug; n is an integer ranging from 1 to 8.Type: GrantFiled: May 17, 2016Date of Patent: June 11, 2019Assignee: NewBio Therapeutics, Inc.Inventors: Nianhe Han, Deqiang An, Di Zeng, Baoxiang Wang, Hang Yang, Li Jian, Chun Yang
-
Patent number: 10280214Abstract: Herein are reported glycosylated repeat-motif-molecule conjugate of the following formula: (repeat-motif-molecule?linkern)m?conjugation partner?(linkero?repeat-motif-molecule)p, wherein n and o are independently of each other and independently for each value of m and p integer values of 0 or 1, and m and p are independently of each other integer values of 0 or 1 or 2 or 3 or 4 or 5 or 6 or 7, and wherein the repeat-motif-molecule conjugate comprises at least one oligosaccharide attached to a glycosylation site. Also reported are encoding nucleic acids and method for producing these repeat-motif-conjugates in mammalian cells.Type: GrantFiled: May 4, 2012Date of Patent: May 7, 2019Assignee: HOFFMANN-LA ROCHE INC.Inventors: Stephan Fischer, Sabine Imhof-Jung, Erhard Kopetzki
-
Patent number: 9522958Abstract: Provided is a cancer therapeutic agent comprising a cancer targeting molecule linked to a CpG oligodeoxynucleotide. Also provided are methods of reducing the size of a tumor or inhibiting the growth of cancer cells in an individual or inhibiting the development of metastatic cancer, comprising administering an effective amount of the cancer therapeutic agent. The methods may also include reducing immunoregulatory T cell activity in the individual.Type: GrantFiled: September 8, 2011Date of Patent: December 20, 2016Assignee: University of Southern CaliforniaInventors: Alan L. Epstein, Leslie A. Khawli
-
Patent number: 9410044Abstract: Embodiments of the invention include linking agents including borate, borazine, or boronate groups and coatings and devices that incorporate such linking agents, along with related methods. Other embodiments are also included herein.Type: GrantFiled: May 2, 2013Date of Patent: August 9, 2016Assignee: SurModics, Inc.Inventor: Aleksey V. Kurdyumov
-
Patent number: 9155800Abstract: A fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A capable of viral entry inhibition; and/or at least one Cationic AntiMicrobial Peptide, polypeptide C.Type: GrantFiled: January 9, 2012Date of Patent: October 13, 2015Assignee: VALIANT BIOPHARMA SDN BHDInventors: Muhammad Sagaf Abu Bakar, Ag., Eng Huan Ung
-
Publication number: 20150147332Abstract: An isolated protein or peptide selected from the group consisting of Bordetella colonization factor A (BcfA) protein and antigenic fragments thereof is described, along with an isolated nucleic acid encoding the same, antibodies that bind to the same, methods of producing an immune response in a mammalian subject in need thereof by administering the proteins, peptides or antibodies, and pharmaceutical compositions comprising the same.Type: ApplicationFiled: September 26, 2014Publication date: May 28, 2015Inventors: Rajendar K. Deora, Meenu Mishra, Neelima Sukumar
-
Publication number: 20150147345Abstract: This document relates to conjugates of a biologically active molecule or a derivative thereof and functionalized (e.g., mono- or bi-functional) polymers (e.g., polyethylene glycol and related polymers) as well as methods and materials for making and using such conjugates.Type: ApplicationFiled: June 12, 2013Publication date: May 28, 2015Inventor: Marek Kwiatkowski
-
Publication number: 20150147752Abstract: The present invention relates to novel iridium-based Ir(III) luminescent complexes, conjugates comprising these complexes as a label and their application, e.g. in the electrochemiluminescence based detection of an analyte.Type: ApplicationFiled: January 30, 2015Publication date: May 28, 2015Inventors: Frank Bergmann, Robert Cysewski, Luisa de Cola, Sebastian Dziadek, Jesus Miguel Fernandez Hernandez, Hans-Peter Josel, Elena Longhi, Christoph Seidel
-
Publication number: 20150147274Abstract: Antibodies which are antagonists of the human HGF receptor (MET), wherein the antibodies specifically bind to amino acid residues 568-741 of human MET (SEQ ID No: 1) with high affinity.Type: ApplicationFiled: November 30, 2012Publication date: May 28, 2015Inventors: Danielle Marie Di Cara, John McCafferty, Ermanno Gherardi, Anthony Richard Pope
-
Patent number: 9040310Abstract: Disclosed herein are antibody-nanoparticle conjugates that include two or more nanoparticles (such as gold, palladium, platinum, silver, copper, nickel, cobalt, iridium, or an alloy of two or more thereof) directly linked to an antibody or fragment thereof through a metal-thiol bond. Methods of making the antibody-nanoparticle conjugates disclosed herein include reacting an arylphosphine-nanoparticle composite with a reduced antibody to produce an antibody-nanoparticle conjugate. Also disclosed herein are methods for detecting a target molecule in a sample that include using an antibody-nanoparticle conjugate (such as the antibody-nanoparticle conjugates described herein) and kits for detecting target molecules utilizing the methods disclosed herein.Type: GrantFiled: April 27, 2011Date of Patent: May 26, 2015Assignee: Ventana Medical Systems, Inc.Inventors: Julia Ashworth-Sharpe, Chol Steven Yun, Zhanna Zhilina, Adrian E. Murillo, Donald D. Johnson, Michael Farrell, Jerome W. Kosmeder, Christopher Bieniarz
-
Publication number: 20150140684Abstract: A target affinity material comprising a biodegradable polymer, wherein the biodegradable polymer comprises one or more solid particles and one or more materials that specifically binds to a target, as well as related methods and kits.Type: ApplicationFiled: July 17, 2014Publication date: May 21, 2015Inventors: Ga-hee KIM, Hyun-ju Kang, Ye-ryoung Yong, Jong-myeon Park
-
Publication number: 20150133618Abstract: The invention discloses a method of separating a biomolecule from at least one other component in a liquid, comprising a step of contacting said liquid with a separation matrix comprising a solid support and polymer chains bound to said solid support. The polymer chains comprise units derived from a first monomer of structure CH2?CH-L-X, where L is a covalent bond or an alkyl ether or hydroxysubstituted alkyl ether chain comprising 2-6 carbon atoms, and X is a sulfonate or phosphonate group.Type: ApplicationFiled: April 22, 2013Publication date: May 14, 2015Inventors: Jesper Hanssen, Gustav Rodrigo, Tobias E Soderman
-
Patent number: 9029509Abstract: The present disclosure relates to binding agents (e.g. antibodies) that bind to and/or modulate the activity of a urokinase plasminogen activator receptor (uPAR/CD87), compositions comprising the antibodies, and methods involving use of the antibodies or compositions.Type: GrantFiled: February 11, 2011Date of Patent: May 12, 2015Assignee: The Regents of the University of CaliforniaInventors: Charles S. Craik, Krishna Sai Duriseti, David H. Goetz
-
Patent number: 9029508Abstract: The present invention relates to engineered multivalent and multispecific binding proteins, methods of making, and specifically to their uses in the prevention, diagnosis, and/or treatment of disease.Type: GrantFiled: April 28, 2009Date of Patent: May 12, 2015Assignee: AbbVie Inc.Inventors: Tariq Ghayur, Susan E. Morgan-Lappe, Edward B. Reilly, Gillian A. Kingsbury, Andrew Phillips, Jieyi Wang, Randy L. Bell, Suzanne M. Norvell, Yingchun Li, Junjian Liu, Hua Ying
-
Publication number: 20150125473Abstract: The present invention concerns a process for the preparation of an antibody conjugate comprising the step of reacting an engineered antibody having a single inter-heavy chain disulfide bond with a conjugating reagent that forms a bridge between the two cysteine residues derived from the disulfide bond.Type: ApplicationFiled: June 19, 2013Publication date: May 7, 2015Inventors: John Burt, Antony Godwin, George Badescu
-
Publication number: 20150125397Abstract: Engineered multivalent and multispecific binding proteins that bind immune cell receptors and/or autoantigens are provided, along with methods of making and uses in the prevention, diagnosis, prognosis and/or treatment of disease.Type: ApplicationFiled: October 6, 2014Publication date: May 7, 2015Inventors: Chee-Ho Choi, Tariq Ghayur, Ann Marshak-Rothstein, Krishna Moody